In vitro carcinogenicity testing: Present and future perspectives in pharmaceutical development

Current Opinion in Drug Discovery and Development

Volumn 4, Issue 1, 2001, Pages 29-35

  Kowalski, L A ^a  

^a Vera Genics Ltd   (Canada)

Author keywords

Cell transformation; Genotoxicity; High throughput screening; In vitro carcinogenicity testing; Mutagenicity

Indexed keywords

CARCINOGEN;

ANIMAL CELL; BACTERIUM; CARCINOGEN TESTING; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOGENETICS; DRUG CARCINOGENICITY; DRUG RESEARCH; DRUG SCREENING; GENE MUTATION; GENOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MAMMAL; MICRONUCLEUS TEST; MUTAGENICITY; NONHUMAN; REVIEW;

ANIMALS; CARCINOGENICITY TESTS; CHEMISTRY, PHARMACEUTICAL; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MUTAGENICITY TESTS;

EID: 0035147462     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Qualitative and quantitative procedures for health risk assessment
2. Prediction of chemical carcinogenicity in rodents from in vitro genetic toxicity assays
3. Cytochromes P450 and species differences in xenobiotic metabolism and activation of carcinogen
4. An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials
5. Mechanisms of action of oxidant carcinogens
6. ICH Harmonised Tripartate Guideline S1b. Testing for Carcinogenicity of Pharmaceuticals
7. Guideline S2b
8. Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test
9. Rapid detection of mutagens and carcinogens
10. Detection of carcinogens as mutagens in the Salmonella/microsome test: Assay of 300 chemicals
11. The significance and interpretation of in vitro carcinogenicity assay results
12. Carcinogens are mutagens: A simple test system combining liver homogenates for activation and bacteria for detection
13. Genotoxicity of ochratoxin A by Salmonella mutagenicity test after bioactivation by mouse kidney microsomes
14. Establishment of a Salmonella tester strain highly sensitive to mutagenic heterocyclic amines
15. Studies on a new mechanism of resistance of L5178Y murine leukemia cells to cytosine arabinoside
16. Selection and characterization of mutations auxotrophic for L-glutamine or resistant to 8-azaguanine in Chinese hamster cells in vitro
17. Genotoxicity of 3′-azido-3′-deoxythymidine in the human lymphoblastoid cell line TK6: Relationships between DNA incorporation, mutant frequency, and spectrum of deletion mutations in HPRT
18. Detection of deletion mutations in pSV2 gpt-transformed cells
19. Summary report on performance of gene mutation assays in mammalian cells in culture
20. Identification of rodent carcinogens and non-carcinogens using genetic toxicity tests: Premises, promises and performance
21. Induction of forward mutations at the thymidine kinase locus of mouse lymphoma cells: Evidence for electrophilic and non-electrophilic mechanisms
22. ++ mouse lymphoma specific gene and chromosomal mutation assay a phase III report of the US Environmental Protection Agency Gene-Tox Program
23. Evaluation of the mouse lymphoma tk assay (microwell method) as an alternative to the in vitro chromosomal aberration test
24. Sister chromatid exchange as an indicator of mutagenesis
25. Relationship between carcinogenicity in rodents and the induction of sister chromatid exchanges and chromosomal aberrations in Chinese hamster ovary cells
26. Evaluation of the micronucleus test using a Chinese hamster cell line as an alternative to the conventional in vitro chromosomal aberration test
27. Genotoxic effects of heterocyclic aromatic amines in human derived hepatoma (HepG2) cells
28. A micromethod for the in vitro micronucleus assay
29. Correlation between induction of DNA fragmentation and micronuclei formation in kidney cells from rats and humans and tissue-specific carcinogenic activity
30. The in situ micronucleus assay: Utility for genotoxicity screening
31. In vitro micronucleus text as replacement for the in vitro chromosomal aberration assay: Industrial experience
32. A quantitative system for assay of malignant transformation by chemical carcinogens using a clone derived from BALB 3T3
33. Quantitative and qualitative studies of chemical transformation of cloned C3H mouse embryo cells sensitive to post-confluence inhibition of cell division
34. In vitro transformation of normal cells to tumor cells by carcinogenic hydrocarbons
35. The pH 6.7 Syrian hamster embryo cell transformation assay for assessing the carcinogenic potential of chemicals
36. The significance of in vitro cells transformation assays for routine testing
37. Cell transformation by chemical agents - A review and analysis of the literature. A report of the US Environmental Protection Agency Gene-Tox program
38. Mutagen-metabolizing enzymes in mammalian cell cultures: Possibilities and limitations for mutagenicity screening
39. Relationship between in vitro cell transformation and in vivo carcinogenesis based on available data on the effects of chemicals
40. Establishment of a highly reproducible transformation assay of a Ras-transfected Balb/c3T3 clone by treatment with promoters
41. Quantitative studies of in vitro transformation by chemical carcinogens
42. Cell transformation induced by bovine papillomavirus DNA as an assay for tumor promoters and chemopreventive agents
43. In vitro determination of carcinogenicity of sixty-four compounds using a bovine papillomavirus DNA-carrying C3H/10T1/2 cell line
44. Use of the Syrian hamster embryo cell transformation assay for carcinogenicity prediction of chemicals currently being tested by the National Toxicology Program in rodent bioassays
45. Performance of tests for cell transformation and gap-junctional intercellular communication for detecting non-genotoxic carcinogenic activity
46. The CAT-Tox (L) assay: A sensitive and specific measure of stress-induced transcription in transformed human liver cells
47. Stress responses to DNA damaging agents in the human colon carcinoma cell line, RKO
48. Multiple stages and genetic alterations in immortalization, malignant transformation and tumor progression of human skin keratinocytes
49. Characteristics of an infinite life span diploid human fibroblast cell strain and a near-diploid strain arising from a clone of cells expressing a transfected v-myc oncogene
50. Role of pharmacokinetics and metabolism in drug discovery and development
51. Ultra-high throughput screening
52. Toxicologic: Cutting edge technologies in molecular toxicology promise to speed drug development
53. Quantitation of transcriptional and clonal selection of single living cells with ß-lactamase as reporter
54. The use of Syrian hamster embryo cells in a high throughput micronucleus screening assay
55. Evaluation of a mini-Ames assay for pharmaceutical compound screening: Use of 96-well microtiter plates for treatment
56. Development of a high throughput assay for detection of repairable adducts by growth inhibition using DNA repair deficient CHO cells (DRAG) test
57. Compound optimization in early- and late-phase drug discovery: Acceptable pharmacokinetic properties utilizing combined physicochemical, in vitro and in vivo screens
58. Virtual combinatorial synthesis and computational screening of new ptential anti-herpes compounds
59. Computer-aided prediction of drug toxicity in high throughput screening
60. Frontier orbital energies, hydrophobicity and steric factors as physical QSAR descriptors of molecular mutagenicity